Pharma BD Deal Intelligence
The $62B deal that transformed Takeda from Japan-centric pharma into a global top-10 company—the largest-ever foreign acquisition by a Japanese firm. Shire's rare disease and plasma therapies gave Takeda $30B+ combined revenue, but $40B+ in debt forced multiple divestitures.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Takeda and Shire announced that they have reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to…
Takeda Pharmaceutical completed its $62-billion acquisition of Shire, the largest-ever foreign acquisition by a Japanese company, creating a global,…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Takeda acquired Shire for approximately $62 billion in the largest-ever foreign acquisition by a Japanese company, gaining a leading rare disease and plasma-derived therapies portfolio and transforming into a global top-10 biopharmaceutical company with over $30 billion in combined revenue.
Assessment window: 5yr post-close.
40K US cases/yr · $10.0B Global UC therapeutics
Ulcerative colitis is a chronic inflammatory bowel disease affecting the colon. Anti-TNFs, vedolizumab, JAK inhibitors, and IL-23 inhibitors provide multiple treatment options for moderate-to-severe disease.
Mild: 5-ASA. Moderate-severe: anti-TNF (infliximab, adalimumab), vedolizumab (Entyvio), JAK inhibitors (tofacitinib, upadacitinib), IL-23 (mirikizumab/Omvoh). Key players: Takeda (Entyvio $5B+), AbbVie (Humira/Skyrizi/Rinvoq), J&J (Remicade/Stelara).
33K US cases/yr · $12.0B Global Crohn's disease therapeutics
Crohn's disease is a chronic inflammatory bowel disease affecting any part of the GI tract. Treatment has been transformed by biologics. IL-23 inhibitors and JAK inhibitors are expanding options.
Anti-TNF (infliximab, adalimumab), vedolizumab, ustekinumab, risankizumab, upadacitinib. Key players: AbbVie (Humira/Skyrizi/Rinvoq), Takeda (Entyvio), J&J (Stelara), Pfizer (pipeline).
25K US cases/yr · $10.0B Global immunoglobulin market
Primary immunodeficiency encompasses >400 genetic disorders affecting the immune system. Immunoglobulin replacement therapy (IV or subcutaneous) is the mainstay for antibody deficiencies.
IVIg/SCIg: Gammagard (Takeda), Privigen/Hizentra (CSL Behring), Gamunex (Grifols), Cuvitru (Takeda). Supply constrained by plasma collection. Key players: Takeda (leading IG franchise), CSL Behring, Grifols.
800 US cases/yr · $5.0B Global HAE therapeutics
HAE is a rare genetic disorder causing recurrent episodes of severe swelling. Lanadelumab (Takhzyro) and berotralstat (Orladeyo) have transformed prophylactic treatment, replacing C1 esterase inhibitor concentrates.
Prophylaxis: lanadelumab (Takhzyro), berotralstat (Orladeyo), C1-INH (Cinryze, Haegarda). Acute: icatibant (Firazyr), ecallantide, C1-INH. Key players: Takeda (Takhzyro, Firazyr), BioCryst (Orladeyo), CSL Behring (Haegarda).
400 US cases/yr · $12.0B Global hemophilia therapeutics
Hemophilia A is an X-linked bleeding disorder due to Factor VIII deficiency. Treatment has evolved from plasma-derived factors to recombinant and extended half-life products, bispecific antibodies, and gene therapy.
Prophylaxis: emicizumab (Hemlibra, bispecific), EHL Factor VIII. Gene therapy: valoctocogene roxaparvovec (Roctavian). Key players: Roche (Hemlibra $4B+), Sanofi/Sobi (Eloctate/Alprolix from Bioverativ), BioMarin (Roctavian), Takeda (Adynovate).
200 US cases/yr · $2.0B Global Gaucher disease therapeutics
Gaucher disease is a lysosomal storage disorder caused by glucocerebrosidase deficiency. ERT and substrate reduction therapy are effective for Type 1. Types 2 and 3 have CNS involvement.
ERT: Cerezyme (imiglucerase, Sanofi), Vpriv (velaglucerase alfa, Takeda/Shire). SRT: eliglustat (Cerdelga, Sanofi). Key players: Sanofi (Cerezyme, Cerdelga), Takeda (Vpriv).
50 US cases/yr · $800M Global Hunter syndrome/MPS II therapeutics
Hunter syndrome (MPS II) is a rare X-linked lysosomal storage disorder caused by iduronate-2-sulfatase deficiency. Enzyme replacement therapy (Elaprase) is available but does not cross the blood-brain barrier for CNS involvement.
ERT: Elaprase (idursulfase, Takeda/Shire). CNS: intrathecal ERT and gene therapy in development. HSCT limited role. Key player: Takeda (Elaprase).
Vyvanse (lisdexamfetamine dimesylate) competes in the US ADHD pharmacotherapy market across three MOA classes, with a structural inflection in 2023 when multiple generic lisdexamfetamine products entered after patent expiry. Within the amphetamine-prodrug/stimulant class, generic lisdexamfetamine (multiple manufacturers including Teva, Amneal, Sandoz, Norwich, 2023+) is the direct intraclass substitute eroding branded Vyvanse share. Broader amphetamine stimulant competitors include Adderall XR (mixed amphetamine salts ER, Shire/Takeda legacy brand and generics), Mydayis (Takeda), Dyanavel XR (amphetamine oral suspension, Tris Pharma), and Adzenys XR-ODT (Neos/Aytu). Within the methylphenidate stimulant class (dopamine/norepinephrine reuptake inhibition with presynaptic DA release), Concerta (OROS methylphenidate, Janssen and generics), Ritalin LA (Novartis and generics), Focalin XR (dexmethylphenidate, Novartis and generics), Quillivant XR, and Jornay PM (Ironshore) are the principal competitors. Non-stimulant MOA classes include the selective norepinephrine reuptake inhibitor Strattera (atomoxetine, Lilly and generics), the alpha-2A adrenergic agonists Intuniv (guanfacine ER, Shire/Takeda and generics) and Kapvay (clonidine ER), and the newer selective dopamine/norepinephrine reuptake inhibitor Qelbree (viloxazine ER, Supernus, approved 2021). Commercial-lead read: Vyvanse's brand exclusivity ended in 2023; the franchise is now under direct generic substitution plus persistent DEA stimulant supply constraints.
Replagal (agalsidase alfa, Takeda/Shire) is a recombinant human alpha-galactosidase A enzyme replacement therapy (ERT) for Fabry disease. It is approved in Europe and ex-US markets but is NOT FDA-approved in the United States, which materially constrains its US commercial threat. Within the ERT MOA class itself, the direct head-to-head competitor is Fabrazyme (agalsidase beta, Sanofi Genzyme), the only FDA-approved ERT for Fabry disease in the US; Fabrazyme holds dominant US share as a result. A biosimilar ERT, pegunigalsidase alfa (Elfabrio, Chiesi/Protalix), was FDA-approved in May 2023 as a second ERT option with a different pegylation profile and represents the newest intraclass US entrant. The adjacent oral MOA class is the pharmacological chaperone, represented by Galafold (migalastat, Amicus Therapeutics), FDA-approved in 2018 for adults with Fabry disease and amenable GLA variants (approximately one-third to one-half of Fabry patients); Galafold competes on oral convenience and chaperone-responsive genotypes. Investigational MOAs include substrate reduction therapy (venglustat, Sanofi, oral GCS inhibitor) and AAV-based gene therapies (e.g., ST-920/isaralgagene civaparvovec, Sangamo, and 4D-310, 4D Molecular Therapeutics) in clinical development. Commercial-lead read: Replagal's US commercial footprint is effectively zero; ex-US it competes directly with Fabrazyme and faces oral/chaperone encroachment from Galafold in chaperone-amenable patients.
Gattex (teduglutide, marketed as Revestive in ex-US markets) is a recombinant GLP-2 analog and is the only FDA-approved therapy in the GLP-2 agonist MOA class for adult and pediatric short bowel syndrome (SBS) patients dependent on parenteral support. Within the GLP-2 analog class itself, the principal pipeline/emerging competitor is apraglutide (Ironwood Pharmaceuticals, previously VectivBio), a long-acting GLP-2 analog that completed the Phase 3 STARS trial in adult SBS with intestinal failure; Ironwood submitted an NDA in 2024. Glepaglutide (Zealand Pharma) is another Phase 3 GLP-2 analog. Outside the GLP-2 class, SBS management remains dominated by supportive/non-pharmacologic modalities rather than competing drug MOAs: parenteral nutrition (PN) itself, anti-secretory and anti-motility agents (PPIs such as omeprazole, H2 blockers, loperamide, codeine, clonidine), bile acid sequestrants (cholestyramine), and pancreatic enzyme replacement are all used adjunctively but do not replace Gattex's intestinal-adaptation MOA. Growth hormone Zorbtive (somatropin, EMD Serono) carries an SBS indication for short-term adult use but is rarely used commercially. Intestinal transplantation remains the surgical alternative for failed medical management. Commercial-lead read: Gattex holds a monopoly in the GLP-2 SBS class today; apraglutide is the principal near-term branded threat and will be the key intra-class competitive watch-item over 2025-2026.
Takeda and Shire announced the $62 billion acquisition on the final day for Takeda to make a firm bid, after Shire had rejected four previous offers across several months of negotiations.
The Royal Court of Jersey sanctioned the acquisition scheme, clearing the final regulatory hurdle for the $62 billion transaction after obtaining approvals from competition authorities.
Takeda completed its $62 billion acquisition of Shire in January 2019 after the Royal Court of Jersey sanctioned the scheme, making Takeda the first Japanese pharma in the global top 10.
Takeda achieved its target of at least $1.4 billion in recurring pre-tax annual cost synergies from the Shire integration by the end of the third fiscal year following deal completion.
Takeda reported $30.1 billion in total revenue for FY2022, a 12.8% increase year-over-year, with rare diseases contributing $5.4B and plasma-derived therapies contributing $5.0B.
Five years post-close, Takeda transformed into a global top-10 pharma with $30B+ revenue and leadership in rare diseases and GI. Debt reduction progressed well and pipeline is productive.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Shire plc (this deal) | 2018 | $62.0B | 8 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2018 deals · Takeda Pharmaceutical Company Ltd. deals · Gastroenterology deals